A Phase 3 interventional study of Venetoclax and Azacitidine in Acute Myeloid Leukemia (AML), sponsored by AbbVie. Completed at 156 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.
Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 63rd largest by enrollment, is one of 16 that started in 2020, is one of 16 in phase 3, and was the 38th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18–59
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 60+
Virginia Commonwealth University · Sites in United States
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 127 · Phase 3 26 · Phase 4 5
First in 2010; this study’s year is marked. 16 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 57 across the 202 interventional studies. Of the 46 that completed or were terminated, 15 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 202 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
43 studies in Leukemia, Myeloid, Acute by AbbVie: 4 open now, 10 under way, 3 of them phase 3. Of 31 finished, 7 (23%) have results posted.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 13th largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2020, is one of 7 in phase 3, and was the 24th registered.
AbbVie’s Leukemia, Myeloid, Acute studies by the year they started, since 2010.
38 of the studies testing venetoclax in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07264010Phase 3Nanfang Hospital, Southern Medical UniversitySorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | 2026-12-30 |
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
Add all 38 to your calendar (.ics) → With an account.
Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, from their registry updates:
Among AbbVie’s 43 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with azacitidine (AZA). Part 3 will be the Dose Finding portion to determine RPTD of venetoclax in combination with AZA. Part 2 and Part 3 Randomization of the study were removed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant meets the following disease activity criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive venetoclax once daily (QD) (Days 1-28) for up to 24 cycles, azacitidine (AZA) QD on Days 1-5 of each 28 day cycle for up to 6 cycles.
Drug: Venetoclax · Drug: Azacitidine
Participants will receive venetoclax QD for up to 24 cycles, AZA QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles to determine recommended phase 3 dose (RPTD).
Drug: Venetoclax · Drug: Azacitidine
Participants will receive venetoclax QD for up to 24 cycles, AZA QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles at the RPTD.
Drug: Venetoclax · Drug: Azacitidine
Tablet: Oral
Also known as: ABT-199, GDC-0199, Venclexta
Subcutaneous (SC) or intravenous (IV) injection
Oral Tablet
Number of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1)
DLTs are any of the hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of venetoclax as described in the protocol and evaluated by the Investigator and the sponsor.
Time frame: Up to 28 days (Cycle 1)
Number of Participants With DLTs of Venetoclax in Combination With Oral AZA (Part 3 Dose Finding Portion)
DLTs are hematologic toxicities consisting of any Grade ≥ 3 neutropenia or thrombocytopenia lasting more than 7 days and nonhematologic toxicities as described in the protocol and evaluated by the Investigator and the Sponsor. In addition, AEs that lead to omitting \> 20% of the scheduled dose within the cycle is considered as a DLT unless clearly related to underlying disease. Treatment delay due to toxicity lasting greater than 14 days since the last dose of Venetoclax is also considered a DLT.
Time frame: Up to 28 days (Cycle 1)
| Milestone | Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2 | Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg | Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg |
|---|---|---|---|---|---|
| Started | 23 | 23 | 20 | 30 | 16 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 23 | 23 | 20 | 30 | 16 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 1 | 1 |
| Withdrew: Death | 1 | 4 | 1 | 1 | 0 |
| Withdrew: Physician decision | 1 | 2 | 2 | 0 | 1 |
| Withdrew: Covid-19 infection | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Not disclosed | 5 | 3 | 8 | 0 | 1 |
| Withdrew: Missing | 1 | 0 | 1 | 1 | 1 |
| Withdrew: Continuing in ongoing study | 13 | 13 | 7 | 26 | 12 |
DLTs are any of the hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of venetoclax as described in the protocol and evaluated by the Investigator and the sponsor.
| Participants | Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2 |
|---|---|---|---|
| Neutropenia | 3 | 4 | 4 |
| Leukopenia | 1 | 0 | 0 |
| Thrombocytopenia | 1 | 0 | 0 |
| Platelet count decreased | 1 | 0 | 0 |
DLTs are hematologic toxicities consisting of any Grade ≥ 3 neutropenia or thrombocytopenia lasting more than 7 days and nonhematologic toxicities as described in the protocol and evaluated by the Investigator and the Sponsor. In addition, AEs that lead to omitting \> 20% of the scheduled dose within the cycle is considered as a DLT unless clearly related to underlying disease. Treatment delay due to toxicity lasting greater than 14 days since the last dose of Venetoclax is also considered a DLT.
| Participants | Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg | Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg |
|---|---|---|
| Neutropenia | 1 | 2 |
| Thrombocytopenia | 1 | 1 |
| Febrile neutropenia | 0 | 1 |
| Fatigue | 0 | 1 |
| Neutrophil count decreased | 1 | 1 |
| Platelet count decreased | 0 | 1 |
| Dizziness | 1 | 0 |
Collected over All-cause mortality and adverse event tables include events reported from the time of informed consent to the interim cutoff date of 05OCT2022. The median time on follow-up was 446, 687, 389 days for Part 1 VEN400_AZA20, VEN400_AZA36, VEN400_AZA50 and 67.5, 275 days for Part 3 Dose Level 1 (VEN400_CC200), Dose Level 2 (VEN400_CC300), respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2 | 3/23 (13%) | 5/23 (21.7%) | 21/23 (91.3%) |
| Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2 | 5/23 (21.7%) | 7/23 (30.4%) | 22/23 (95.7%) |
| Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2 | 1/20 (5%) | 5/20 (25%) | 20/20 (100%) |
| Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg | 1/30 (3.3%) | 5/30 (16.7%) | 29/30 (96.7%) |
| Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg | 1/16 (6.3%) | 3/16 (18.8%) | 16/16 (100%) |
| Event | Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2 | Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg | Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg |
|---|---|---|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 1/23 | 1/23 | 0/20 | 0/30 | 2/16 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 2/23 | 1/23 | 1/20 | 1/30 | 0/16 |
| NEUTROPENIABlood and lymphatic system disorders | 0/23 | 0/23 | 1/20 | 2/30 | 0/16 |
| COLITISGastrointestinal disorders | 0/23 | 0/23 | 0/20 | 0/30 | 1/16 |
| ANORECTAL INFECTIONInfections and infestations | 0/23 | 0/23 | 0/20 | 0/30 | 1/16 |
| NEUTROPHIL COUNT DECREASEDInvestigations | 0/23 | 0/23 | 0/20 | 0/30 | 1/16 |
| LEUKOPENIABlood and lymphatic system disorders | 0/23 | 0/23 | 1/20 | 0/30 | 0/16 |
| COVID-19Infections and infestations | 0/23 | 0/23 | 1/20 | 0/30 | 0/16 |
| COVID-19 PNEUMONIAInfections and infestations | 1/23 | 1/23 | 1/20 | 0/30 | 0/16 |
| ACUTE KIDNEY INJURYRenal and urinary disorders | 0/23 | 0/23 | 1/20 | 0/30 | 0/16 |
| Event | Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2 | Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg | Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg |
|---|---|---|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 13/23 | 16/23 | 16/20 | 10/30 | 9/16 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 8/23 | 13/23 | 11/20 | 7/30 | 6/16 |
| NAUSEAGastrointestinal disorders | 6/23 | 3/23 | 4/20 | 15/30 | 9/16 |
| VOMITINGGastrointestinal disorders | 3/23 | 2/23 | 0/20 | 9/30 | 9/16 |
| DIARRHOEAGastrointestinal disorders | 6/23 | 2/23 | 5/20 | 13/30 | 7/16 |
| COVID-19Infections and infestations | 2/23 | 5/23 | 2/20 | 3/30 | 6/16 |
| ANAEMIABlood and lymphatic system disorders | 4/23 | 8/23 | 7/20 | 3/30 | 4/16 |
| LEUKOPENIABlood and lymphatic system disorders | 6/23 | 7/23 | 7/20 | 4/30 | 4/16 |
| PLATELET COUNT DECREASEDInvestigations | 4/23 | 3/23 | 3/20 | 3/30 | 5/16 |
| CONSTIPATIONGastrointestinal disorders | 1/23 | 5/23 | 1/20 | 8/30 | 3/16 |
| Age, Continuous(years) | Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2 | Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg | Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg | Total |
|---|---|---|---|---|---|---|
| Mean | 53.1 ± 13.97 | 57.3 ± 13.89 | 55.6 ± 16.26 | 58.8 ± 12.70 | 54.1 ± 16.94 | 55.78 ± 14.75 |
| Sex: Female, Male(Participants) | Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2 | Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg | Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg | Total |
|---|---|---|---|---|---|---|
| Female | 13 | 11 | 10 | 16 | 6 | 56 |
| Male | 10 | 12 | 10 | 14 | 10 | 56 |
| Race (NIH/OMB)(Participants) | Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2 | Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2 | Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg | Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 6 | 8 | 5 | 2 | 27 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 17 | 16 | 12 | 25 | 14 | 84 |
| More than one race | 0 | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
Showing the first 100 of 156 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Mar 2020 to primary completion in Sep 2022, 30 months.
Results were first posted in Aug 2025, 2 years 10 months after primary completion. A results delay was requested in Aug 2023.
Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 30 months is below that.
Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Venetoclax · Azacitidine